Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akili, Inc. stock logo
AKLI
Akili
$0.25
+4.2%
$0.28
$0.19
$1.67
$19.49M1.991.93 million shs144,767 shs
Bioventus Inc. stock logo
BVS
Bioventus
$4.15
-3.7%
$4.96
$0.86
$6.08
$328.56M0.5145,918 shs118,230 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.50
+3.4%
$1.64
$0.68
$4.58
$44.16M1.66135,717 shs40,413 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$6.86
$8.82
$3.78
$13.62
$378.84M1.67181,839 shs129,153 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akili, Inc. stock logo
AKLI
Akili
+4.32%+6.32%-12.04%-14.64%-79.22%
Bioventus Inc. stock logo
BVS
Bioventus
+0.47%-7.11%-20.77%-0.46%+322.55%
DarioHealth Corp. stock logo
DRIO
DarioHealth
+9.85%+22.88%0.00%-30.95%-57.97%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
+0.15%-11.83%-23.44%-21.15%+19.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akili, Inc. stock logo
AKLI
Akili
2.9759 of 5 stars
3.55.00.00.01.11.71.3
Bioventus Inc. stock logo
BVS
Bioventus
3.6524 of 5 stars
3.50.00.00.02.84.21.9
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.9009 of 5 stars
3.52.00.00.01.80.81.3
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akili, Inc. stock logo
AKLI
Akili
3.00
Buy$4.001,512.90% Upside
Bioventus Inc. stock logo
BVS
Bioventus
3.00
Buy$7.6784.74% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37257.78% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest PLSE, BVS, AKLI, and DRIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/13/2024
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$6.00 ➝ $9.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akili, Inc. stock logo
AKLI
Akili
$1.68M11.60N/AN/A$0.75 per share0.33
Bioventus Inc. stock logo
BVS
Bioventus
$512.34M0.64$0.77 per share5.42$2.80 per share1.48
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M2.17N/AN/A$2.14 per share0.70
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K541.21N/AN/A$0.81 per share8.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akili, Inc. stock logo
AKLI
Akili
-$59.49M-$0.76N/AN/AN/A-3,545.47%-76.34%-56.48%5/10/2024 (Estimated)
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$2.52N/A10.38N/A-30.49%2.25%0.62%5/21/2024 (Estimated)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/9/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.89N/AN/AN/A-112.74%-61.09%5/9/2024 (Estimated)

Latest PLSE, BVS, AKLI, and DRIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.54-$0.41+$0.13-$0.41$3.57 million$3.62 million
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/12/2024Q4 2023
Bioventus Inc. stock logo
BVS
Bioventus
$0.06$0.07+$0.01$0.24$124.84 million$135.42 million
2/29/2024Q4 2023
Akili, Inc. stock logo
AKLI
Akili
-$0.26-$0.14+$0.12-$0.14$1.07 million$0.75 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akili, Inc. stock logo
AKLI
Akili
N/AN/AN/AN/AN/A
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akili, Inc. stock logo
AKLI
Akili
0.09
6.02
6.02
Bioventus Inc. stock logo
BVS
Bioventus
1.66
1.53
1.01
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
6.76
6.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akili, Inc. stock logo
AKLI
Akili
53.12%
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%

Insider Ownership

CompanyInsider Ownership
Akili, Inc. stock logo
AKLI
Akili
10.10%
Bioventus Inc. stock logo
BVS
Bioventus
29.10%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
69.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akili, Inc. stock logo
AKLI
Akili
6878.60 million70.66 millionOptionable
Bioventus Inc. stock logo
BVS
Bioventus
97079.17 million56.13 millionNot Optionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.44 million26.47 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
6155.23 million16.73 millionOptionable

PLSE, BVS, AKLI, and DRIO Headlines

SourceHeadline
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
businesswire.com - April 24 at 4:05 PM
Pulse Biosciences to raise $60MPulse Biosciences to raise $60M
massdevice.com - March 29 at 10:48 AM
Q4 2023 Pulse Biosciences Inc Earnings CallQ4 2023 Pulse Biosciences Inc Earnings Call
finance.yahoo.com - March 29 at 10:48 AM
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
investorplace.com - March 28 at 11:31 PM
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
finance.yahoo.com - March 28 at 7:45 PM
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial ResultsPulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
businesswire.com - March 28 at 4:12 PM
Pulse Biosciences Announces Plans to Initiate a Rights OfferingPulse Biosciences Announces Plans to Initiate a Rights Offering
businesswire.com - March 28 at 4:10 PM
PLSE Apr 2024 25.000 callPLSE Apr 2024 25.000 call
finance.yahoo.com - March 17 at 10:01 AM
PLSE Oct 2024 17.500 callPLSE Oct 2024 17.500 call
finance.yahoo.com - March 17 at 12:13 AM
PLSE Oct 2024 12.500 callPLSE Oct 2024 12.500 call
finance.yahoo.com - March 16 at 2:13 PM
PLSE Jul 2024 2.500 putPLSE Jul 2024 2.500 put
finance.yahoo.com - March 16 at 2:13 PM
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
businesswire.com - March 14 at 4:05 PM
Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearancePulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance
msn.com - March 13 at 7:07 PM
FDA clears pulsed field ablation electrode tech from Pulse BiosciencesFDA clears pulsed field ablation electrode tech from Pulse Biosciences
massdevice.com - March 11 at 1:28 PM
What to know about low blood pressure with a high pulseWhat to know about low blood pressure with a high pulse
medicalnewstoday.com - March 10 at 2:46 PM
FDA clears Pulse Biosciences soft tissue ablation systemFDA clears Pulse Biosciences' soft tissue ablation system
investing.com - March 10 at 2:46 PM
Pulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode SystemPulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode System
markets.businessinsider.com - March 9 at 1:21 AM
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode SystemPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System
stockhouse.com - March 8 at 3:19 PM
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode SystemPulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
businesswire.com - March 8 at 1:17 PM
Pulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablationPulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablation
massdevice.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock UpPulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up
markets.businessinsider.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
finance.yahoo.com - February 14 at 12:51 PM
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility StudyPulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
businesswire.com - February 14 at 8:00 AM
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In GrowthCompanies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
finance.yahoo.com - February 2 at 12:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akili logo

Akili

NASDAQ:AKLI
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.
Bioventus logo

Bioventus

NYSE:BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.